Women's health in emerging markets
Why can understanding and improving women’s health in emerging markets be challenging? What strategies can global pharma develop to support women and overcome these challenges? Associate Director Rachel Howard and Research Manager Helen Mace discuss why market research is useful for understanding behaviours and attitudes to different women’s health issues in emerging markets.
Cool heads in a crisis?
Understanding the role pharmaceutical companies can play in fighting today’s global health pandemics
First there was Ebola and now there is Zika; two official World Health Organization (WHO) Public Health Emergencies of International Concern (PHEIC) within as many years. Whenever global health crises such as these emerge, the pharmaceutical industry comes under intense scrutiny for not having an immediate solution available. Part of the problem is that prevention is not always financially viable; the substantial R&D costs of developing vaccines or treatments for all known and potential threats that may or may not one day develop into global pandemics is not a feasible burden for the industry to carry alone.
Research Partnership has published a new Living with Living with Lupus (SLE) market report for 2017
SLE is a progressive and debilitating disease which affects 5 million people worldwide. Living with Lupus (SLE) is a quantitative study conducted online amongst patients in the US and France and Germany. The report consists of 30-minute online interviews with 262 SLE patients (including those with lupus nephritis); fifteen follow-up qualitative interviews were also conducted. All patients were required to be on an immunosuppressant or biologic therapy; the final sample includes 15-20% on biologics.
Biosimilars: Bringing patients into the conversation
Published in eyeforpharma January 2017 by Mariel Metcalfe
In a recent white paper, we explored the impact that biosimilars are having and likely to have on the rising cost of RA treatment. We looked at physician attitudes to biosimilars and the challenges manufacturers face in gaining widespread acceptance.
Access and elimination: the future of DAAs in hepatitis C
Published in Pharmaphorum January 2017
The dramatic improvements in safety, efficacy, tolerability and convenience from the first wave of direct-acting antivirals (DAAs) have made a substantial contribution to changing both the treatment paradigm and the long-term prognosis for hepatitis C.
The arrival of interferon-free, orally administered direct-acting antivirals (DAAs) in 2014 was a leap forward for the treatment of hepatitis C (HCV), a disease responsible for some 700,000 deaths globally each year.